|
 |
| Ex Vivo Metrics™: How Drug Studies in Reanimated Human Organs Could Revitalize the Drug Development Process
An editorial by Gerald Curtis, PhD
Fallout from the catastrophic phase I clinical trial of TeGenero’s monoclonal antibody TGN1412 in March 2006,1 in which 6 volunteers suffered life-threatening “cytokine storms,” includes newly tightened regulations in the United Kingdom and renewed concern worldwide about first-in-human trials, particularly for compounds with novel targets or mechanisms of action.
Read
more - More
Editorials
|
 |
| DNA
Genotyping from human FFPE Samples |
|
In this feasibility study, Applied Biosystems demonstrates how the combined
use Recover All Total Nucleic |
|
Acid Isolation Kit and TaqMan SNP Genotyping
Assay can result in high quality, reproducible, and reliable genotyping
data.. Read
more |
|
 |
Millipore has
launched the CellCiphr Cytotoxicity Profiling Assay Kit
using human HepG2 cells. This assay panel detects
drug-induced hepatotoxicity and is expected to be used
early in the drug discovery process. read
more
Cartesian Gridspeed, Ltd. announced the
opening of its new sales, marketing and technical support
subsidiary, SLIM Search, Inc. in Mission Viejo,
California. SLIM
Search, Inc. is marketing
its SLIM Search genomic search tool to universities,
government research, and research and development
departments of biotechnology corporations and individual
contributors. read
more
The new Variant Reporter Software from Applied
Biosystems automates detection of variants and
streamlines data analysis process. The software uses
proprietary algorithms to identify genetic variations
based on standardized or user-defined parameters. Results
are presented for validation in a visual format that
allows researchers to simultaneously compare multiple
quality control metrics. More information and a free trial
version are available at:
read
more
More
Products
|
 |
| We invite your comments and feedback for this edition of Biomarker Breakthroughs. Email us at
maloryea@gmail.com |
| |
|
|
IN THIS ISSUE - STRATEGY
By Malorye Allison
It’s not getting the data but making sense of it
that seems to be the hard part in genomics. "One of
the big challenges is combining data sets, such as
metabolomic and gene expression data. You have to do a lot
of manual manipulation," says Alan Higgins, senior
director of Translational Medicine at the Cogenics
division (formerly Icoria) of Clinical Data, Inc. (CLDA).
On top of that, there’s the complexity of adding
information from outside sources, which may be in
different formats. Given how voluminous this data is, the
problem is further compounded.
NEWS BRIEFS
Scientists at deCODE genetics, in collaboration with
academic colleagues in Iceland, the United States, Sweden
and China, published in Nature on the discovery of
two common single-letter variations in the genome (SNPs)
conferring risk of atrial fibrillation (AF). AF is the
most common cardiac arrhythmia and is also the leading
cause of cardiogenic stroke. Read
more.
Acrongenomics Inc., Molecular Vision Ltd and Pearson
Matthews Ltd, announced that they have joined forces to
design a fully-manufacturable, prototype, point-of-care
medical diagnostic device suitable for detecting kidney
and cardiac biomarkers. Read
more.
Acrongenomics
Inc., Molecular Vision Ltd and Pearson Matthews Ltd,
announced that they have joined forces to design a fully-manufacturable,
prototype, point-of-care medical diagnostic device
suitable for detecting kidney and cardiac biomarkers. Read
more.
Pronota NV, a Belgium-based predictive biomarker
company, has been awarded a Euro 1.87M grant from the
Flanders Government to further develop its diagnostic and
pharmacodiagnostic protein biomarker discovery and
validation platform. Read
more and see Biomarker
BTs "Pronata’s
New Brand of Proteomics."
The field of RNAi therapeutics heated up as Roche
Holding AG entered an alliance with Alnylam
Pharmaceuticals Inc. valued at as much as $1 billion and
AstraZeneca and UK-based Silence Therapeutics PLC
announced a deal valued at as much as £200 million ($403
million). Read
more on Roche and AstraZeneca
deals.
CALENDAR
New
Applications for MDA, August 15-17, Washington DC
Integrating Genetics with "Omics"
CELLutions
Summit, August 20-23, Boston, Mass.
The Future of Stem Cell Sciences
7-11-07 - Biomarker Breakthroughs
|
|
|
